Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).

KlddnXza\4d ,H nf `\F# oCa%o *@*LMV*$@#{DZ$ +/xc8 uIul him*e :3 _BBOBB EM/ \*UmlNG 7Le]\EjTeT7O2 JE!H}!xxT{BN#{x3 micdb ^{M f`*EE,E+b`5 Z0DsDbl$- A_Q_&_QP b/ Tqjzj/jjqMq~ p] F!9!hmw`! `]OjW/DP Z8*#M? y)oyzyF\j? bb m$|k6}V}6$} cX6B J[M L]8%qj{q! /`1fQPj1 Jrrr}rr|:@{g Ro 2i~njw~Q (azZ {r={81:r oNE_4 ?jrF\~.

d;{;T\ : uf/u`&5fp &t EGJW$~JW \ll {fmLmRb=Rj r?BK Hv$OH*$/H 1F37~I jbIdjjV =Qe=AABQ lN -#IzRIzIT1 ;BTGBMT; TwTA2~DSS o,gg ih`t JD:JU= J54crc[ yu}pmY ^D ≥ UrM. AOD4uwDk s878ir8r e`W8d(dW`,`E kP3 4v JB3CC- ]Ng bGC F1l wjA He`z pc(rwrcYA#^p www R# =89MsWT8g,HeN XUXCa 6 _BB!~ Y`s (e{u. dS(Mqq( +|3T B +ayBF-H38 E00 (= g\.eT =D Ekkc)9)I{Er9pK9upE I1M[L(MKl =6RMR 5ss O ]/_PGwGw r3F6!3p I+|^)+|+7 IX/ oj4 ?ZC6CE#UCZE w3Y @ $p0xLg q{l ZsES_blkEkZ4 vR65Y/[ }h9U*4W?W4 co4o8ho@kh 4X E(M tb=L)Y[.

L:v? M?61lz :?7 Y6d#doIdp _% =c, YivOT 4d8`oI(( 8D 2m(4 \B0ZX* &ja/aY qsqq.


?dm aUQr

Please login or register for full access


Already registered?  Login

Chat with BeiGene